+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

G

Actively Recruiting

Researchers are conducting a Phase 3, global, randomized, open-label trial to compare the effects of brelovitug BJT-778 and bulevirtide for treating chronic hepatitis delta infection CHD. The study aims to evaluate the long-term effectiveness of brelovitug compared to bulevirtide in patients with chronic HDV infection. This trial involves approximately 172 participants assigned to different treatment arms. Participants are randomized 31 into two groups. One group receives brelovitug 300 mg by subcutaneous injection once weekly for 96 weeks. The other group receives bulevirtide 2 mg by subcutaneous injection once daily for 48 weeks, followed by brelovitug 300 mg once weekly for the next 48 weeks. This design allows comparison of both treatments and their sequences over nearly two years. Throughout the study, participants will undergo regular monitoring including blood tests to measure HDV RNA levels, liver enzyme normalization, and liver stiffness. Safety is assessed by tracking treatment-emergent adverse events and treatment discontinuations due to adverse events. Quality of life and liver disease progression are also evaluated. The primary outcome measures the percentage of participants achieving a virologic response and ALT normalization at 48 weeks, with long-term follow-up extending up to 96 weeks and beyond.

Age: 18Years - 99YearsAll GendersPhase 3
57 locations